Lorena Mendez-Gonzalez
Salamanca, CL, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Neutrophil-mediated trogocytosis as a new mechanism of action of daratumumab.
Journal: Blood neoplasia
Published: February 11, 2025
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
Journal: International journal of molecular sciences
Published: March 14, 2024
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Journal: Cells
Published: December 23, 2020
Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma.
Journal: Cancers
Published: August 31, 2020
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Journal: Haematologica
Published: July 20, 2019
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
Journal: Journal of hematology & oncology
Published: April 04, 2017
The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 29, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026